Who Paid My Doc
Johannes Coetzee
Foot and Ankle Surgery Edina, MN Medical Doctor
NPI 1891729000 CMS profile 86047
4010 W 65Th St, Edina, MN 55435
General payments
$4,666,458
Research payments
$22,750
Ownership & investment interest
$2,873,033
Research they led as principal investigator
$58,020
Through program year 2025, Johannes Coetzee of Edina, MN is reported in the CMS Open Payments database as having received $4,666,458 across 428 general payments and $22,750 in research payments paid to them. Separately, studies naming them as principal investigator received $58,020 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $2,873,033 across 11 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
18 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $198,013 | 60 | |
| 2025 | Research | $325 | 1 | |
| 2024 | General | $198,851 | 38 | |
| 2024 | Research | $2,925 | 6 | |
| 2023 | General | $241,536 | 30 | |
| 2023 | Research | $5,688 | 6 | |
| 2022 | General | $1,290,935 | 56 | |
| 2022 | Research | $13,812 | 7 | |
| 2021 | General | $335,741 | 65 | |
| 2020 | General | $2,031,483 | 97 | |
| 2019 | General | $369,899 | 82 | |
| 2025 | Ownership | $609,485 | 1 | |
| 2024 | Ownership | $99,000 | 1 | |
| 2023 | Ownership | $102,323 | 1 | |
| 2022 | Ownership | $68,680 | 1 | |
| 2021 | Ownership | $145,931 | 2 | |
| 2020 | Ownership | $99,754 | 2 | |
| 2019 | Ownership | $1,747,861 | 3 |
Beside peers
- Johannes Coetzee
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Johannes Coetzee were reported at $198,013. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Johannes Coetzee | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $369,899 | $1,327 | $279–$5,421 | $163 |
| 2020 | $2,031,483 | $795 | $121–$3,473 | $114 |
| 2021 | $335,741 | $1,289 | $201–$4,963 | $132 |
| 2022 | $1,290,935 | $1,539 | $270–$6,067 | $149 |
| 2023 | $241,536 | $1,117 | $257–$5,264 | $160 |
| 2024 | $198,851 | $1,064 | $235–$4,944 | $164 |
| 2025 | $198,013 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
83
Drug cost
$705
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Celecoxib | Generic | 28 | $362 | |
| Meloxicam | Generic | 22 | $215 | |
| Cephalexin | Generic | 20 | $118 | |
| Amoxicillin | Generic | 13 | $10 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 84 billing codesPaid by Medicare
$118,080
Medicare patients
316
Services billed
1,554
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 73% | |
| High blood pressure | 54% | |
| Ischemic heart disease | 20% | |
| Depression | 20% | |
| Osteoporosis | 17% | |
| Cancer | 16% | |
| Atrial fibrillation | 14% | |
| Diabetes | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 41 | 314 | $217 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
448 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Minnesota
Jeffrey Seybold
Foot and Ankle Surgery · Edina, MN
Ruixian Yue
Foot and Ankle Surgery · Woodbury, MN
Michael Anderson
Foot and Ankle Surgery · Woodbury, MN
Benjamin Williams
Foot and Ankle Surgery · Bloomington, MN
Joseph Bellamy
Foot and Ankle Surgery · Edina, MN
Jessica Downes
Foot and Ankle Surgery · Minneapolis, MN
Related records
Foot and Ankle Surgery in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.